Drug Controller General of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila\u2019s \u2018Virafin\u2019 for treating the patients showing moderate COVID-19 symptoms.<\/p>\n\n\n\n
Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, resulted in their faster recovery.<\/p>\n\n\n\n
For the development of Virafin, Zydus appreciated the support provided by DBT-BIRAC COVID 19 Research Consoritum through NBM, for conducting the Phase II human clinical trial studies.<\/p>\n\n\n\n
The studies confirmed the safety, tolerability and efficacy of Virafin. The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels.<\/p>\n\n\n\n
About Zydus Cadila: Also known as Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat.<\/p>\n","protected":false},"excerpt":{"rendered":"
Drug Controller General of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila\u2019s \u2018Virafin\u2019 for treating the patients showing moderate COVID-19 symptoms. Daily Current Affairs Quiz 2021 Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, resulted in their faster recovery. For […]<\/p>\n","protected":false},"author":404,"featured_media":41396,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1403],"tags":[],"offerexpiration":[],"class_list":["post-41395","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-affairs-april-2021"],"_links":{"self":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/41395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/users\/404"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/comments?post=41395"}],"version-history":[{"count":2,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/41395\/revisions"}],"predecessor-version":[{"id":41428,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/41395\/revisions\/41428"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media\/41396"}],"wp:attachment":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media?parent=41395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/categories?post=41395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/tags?post=41395"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/offerexpiration?post=41395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}